Core Viewpoint - Meikang Bio (SZ300439) has received preliminary approval for an environmental impact assessment for a new production project of POCT in vitro diagnostic rapid testing products, with a total investment of 500 million yuan [1]. Group 1: Company Overview - Meikang Bio primarily engages in the research, development, production, and sales of in vitro diagnostic products, as well as providing third-party medical diagnostic services [3]. Group 2: Financial Data - The company's market capitalization is 3.939 billion yuan [4]. - Projected operating revenue for 2024 is 1.736 billion yuan, with a decline to 1.136 billion yuan in 2025 [4]. - Expected net profit attributable to the parent company for 2024 is 2.940 billion yuan, slightly increasing to 2.956 billion yuan in 2025 [4]. - The net asset return rate is projected to be 9.14% in 2024, dropping to 2.05% in 2025 [4]. - The gross profit margin is expected to decrease from 44.55% in 2024 to 39.64% in 2025 [4]. - Operating cash flow is projected to be 398 million yuan in 2024, decreasing to 145 million yuan in 2025 [4]. - Accounts receivable is expected to be 553 million yuan in 2024, increasing to 575 million yuan in 2025 [4].

每经记者｜金喆 每经编辑｜文多 万孚生物还表示，公司已就业绩预告修正的相关事项与会计师事务所进行了沟通，双方在本次业绩预告 修正方面不存在分歧。 值得注意的是，本次修正仅涉及归母净利润，扣除非经常性损益后的净利润指标未发生变动，仍预计亏 损750万元至1500万元。 2026年业绩增长较乐观 发布2025年业绩预告不到一个月后，万孚生物（SZ300482，股价20.65元，市值96.66亿元）就披露上述 业绩的修正公告，预计2025年归母净利润将从此前预告的盈利4600万元至6900万元，修正为亏损4460万 元至6760万元。 记者注意到，导致此次业绩"变脸"的核心原因，是一项会计处理方式变更。公司决定将已终止的股权激 励计划中约1.136亿元的费用一次性计入当期损益，这一调整使得公司净利润骤降超亿元。 2026年2月2日，万孚生物相关人士向《每日经济新闻》记者回应称，2025年是公司的"阵痛期"，并对新 一年的业绩反弹持乐观预期。 公司业绩预盈转为预亏 根据万孚生物1月30日发布的《2025年度业绩预告修正公告》，公司预计2025年归母净利润为亏损4460 万元至6760万元，与上年同期盈利5.62亿元相 ...

1. Report Title and Date - The report is titled "Convertible Bond Industry Chain Big Map - February 2026" and was issued on February 3, 2026 [1] 2. Analysts and Contact Information - Analysts are Yang Yewei and Wang Sufang, with their respective license numbers S0680520050001 and S0680524060002, and email addresses yangyewei@gszq.com and wangsufang@gszq.com [2][3] 3. Hot Topics and Related Convertible Bonds 3.1 "Brain - Machine Interface" - Convertible bonds related to this topic include Lepu Convertible Bond 2, Yiwei Convertible Bond, Kelan Convertible Bond, Jiahe Convertible Bond, and Seli Convertible Bond, with details such as their prices, premiums, balances, and associations with the brain - machine interface provided [5] 3.2 "Commercial Spaceflight" (Part 1) - Convertible bonds include Qifan Convertible Bond, Lion Convertible Bond, Ruike Convertible Bond, etc., with information about their industries, prices, and associations with the commercial spaceflight field [7] 3.3 "Commercial Spaceflight" (Part 2) - Convertible bonds like Tian23 Convertible Bond, Guoli Convertible Bond, and Mengsheng Convertible Bond are related, and their details are presented [10] 4. Industry Chains and Related Convertible Bonds 4.1 Power, Electrical Equipment Industry Chain - It includes segments such as power generation, power equipment, and energy storage, with a list of related convertible bonds like Jieneng Convertible Bond, Jinke Convertible Bond, etc. The top 10 convertible bonds by trading volume in January are also provided, including details like trading volume, price, and premiums [13][15] 4.2 Mining, Non - ferrous Metals, and Chemical Industry Chain - Covers various segments such as basic chemicals, chemical fibers, and coal. Related convertible bonds are listed, and the top 10 convertible bonds by January trading volume are presented, including their trading volumes, prices, and other indicators [17][19] 4.3 Machinery, Transportation, and Automobile Industry Chain - Comprises machinery, automobile parts, and logistics segments. Related convertible bonds are listed, and the top 10 convertible bonds by January trading volume are shown, including trading volumes, prices, and premiums [22][24] 4.4 Electronics Industry Chain - Includes semiconductor materials, electronic chemicals, etc. Related convertible bonds are listed, and the top 10 convertible bonds by January trading volume are provided, with details like trading volume, price, and premiums [27][32] 4.5 Military and TMT Industry Chain - Involves communication equipment, military, computer, and media segments. Related convertible bonds are listed, and information about some convertible bonds' trading volume, price, and other aspects in January is presented [35][38] 4.6 Real Estate Industry Chain - Covers building materials, construction engineering, and household appliances segments. Related convertible bonds are listed, and the top 10 convertible bonds by January trading volume are shown, including trading volumes, prices, and premiums [41][46] 4.7 Financial Industry Chain - Divided into non - banking finance and banking segments. All related convertible bonds are listed, and information about their trading volume, price, and other indicators in January is provided [49][52] 4.8 Light Industry and Downstream Consumption Industry Chain - Encompasses papermaking, agriculture, forestry, animal husbandry, and fishery, and other segments. Related convertible bonds are listed, and the top 10 convertible bonds by January trading volume are presented, including trading volumes, prices, and premiums [55][57] 4.9 Pharmaceutical and Biological Industry Chain - Includes pharmaceutical product production, medical devices, and pharmaceutical circulation. Related convertible bonds are listed, and the top 10 convertible bonds by January trading volume are provided, with details like trading volume, price, and premiums [60][64] 4.10 Environmental Protection Industry Chain - Covers environmental monitoring, comprehensive treatment, and waste treatment. Related convertible bonds are listed, and the top 10 convertible bonds by January trading volume are shown, including trading volumes, prices, and premiums [67][69]

Group 1 - On February 2, 2023, Hotgen Biotech experienced a decline of 5.36% with a trading volume of 211 million yuan. The financing data indicated a net buying of 1.17 million yuan for the day, with a total financing and margin balance of 156 million yuan [1] - The financing balance of Hotgen Biotech was reported at 154 million yuan, accounting for 1.21% of the circulating market value, which is below the 50th percentile level over the past year, indicating a low position [1] - In terms of securities lending, Hotgen Biotech had a securities lending balance of 2.27 million yuan, which is above the 90th percentile level over the past year, indicating a high position [1] Group 2 - As of September 30, 2023, Hotgen Biotech had 7,833 shareholders, an increase of 12.9% from the previous period. The average circulating shares per person decreased by 11.43% to 11,835 shares [2] - For the period from January to September 2023, Hotgen Biotech reported a revenue of 310 million yuan, a year-on-year decrease of 19.8%. The net profit attributable to the parent company was -109 million yuan, a significant decrease of 168.12% [2] - Since its A-share listing, Hotgen Biotech has distributed a total of 440 million yuan in dividends, with 17.34 million yuan distributed over the past three years [3]

Group 1 - The core point of the news is that Mingde Biological experienced a slight decline in stock price, with a trading volume of 59.55 million yuan on February 2, and notable financing activities indicating a high level of market interest [1] - On February 2, Mingde Biological had a financing buy-in amount of 9.26 million yuan and a net financing buy of 0.53 million yuan, with a total financing and securities balance of 130 million yuan, which is 2.91% of its circulating market value [1] - The company’s main business includes the research, production, sales, and service of in vitro diagnostic reagents and instruments, with a revenue composition of 65.04% from in vitro diagnostic products, 21.91% from third-party medical testing, and 13.05% from agency business and others [1] Group 2 - As of January 20, the number of shareholders of Mingde Biological decreased by 15.73% to 24,800, while the average circulating shares per person increased by 18.66% to 6,302 shares [2] - For the period from January to September 2025, Mingde Biological achieved an operating income of 227 million yuan, a year-on-year increase of 0.53%, but the net profit attributable to the parent company decreased by 83.30% to 13.52 million yuan [2] - The company has distributed a total of 1.76 billion yuan in dividends since its A-share listing, with 875 million yuan distributed in the last three years [2]

Core Viewpoint - Wanfu Biology (SZ300482) has revised its 2025 profit forecast from a profit of 46 million to 69 million yuan to a loss of 44.6 million to 67.6 million yuan due to a change in accounting treatment [1][3] Group 1: Financial Performance - The revised forecast indicates a year-on-year decline in net profit attributable to shareholders of 107.94% to 112.04%, compared to a profit of 562 million yuan in the same period last year [1][2] - The adjustment in accounting treatment involved recognizing approximately 113.6 million yuan of expenses related to a terminated equity incentive plan in the current period, leading to a significant drop in net profit [3] Group 2: Market and Industry Context - The IVD (in vitro diagnostics) industry is currently experiencing a downturn, with total revenue for the first three quarters of 2025 at 27.62 billion yuan, a year-on-year decrease of 14.5%, and net profit down 26.4% [4] - The company anticipates that 2025 will be a low point for both the industry and itself, but expects a rebound in 2026, describing the upcoming year as a period of "light load" and clearer growth trends [4][5] Group 3: Business Outlook - The company expects domestic business to experience a recovery, particularly in hospital-based operations, while overseas markets are projected to maintain healthy growth due to early expansion efforts [5] - New business initiatives, such as respiratory testing in the U.S., are expected to contribute to sustained growth in international markets [5]

Group 1: 2025 Annual Performance Forecast - The company expects a net profit attributable to shareholders of 71 million to 85 million yuan for 2025, a decrease of 10,729.53 million to 12,129.53 million yuan compared to the previous year, representing a year-on-year decline of 55.80% to 63.08% [1] - The forecasted net profit attributable to shareholders after deducting non-recurring gains and losses is estimated to be between 13 million and 15.6 million yuan, a decrease of 2,229.79 million to 2,489.79 million yuan compared to the previous year, reflecting a year-on-year decline of 58.84% to 65.70% [1] Group 2: Previous Year Performance - In the previous year, the total profit was 21,064.01 million yuan, with a net profit attributable to shareholders of 19,229.53 million yuan and a net profit after deducting non-recurring gains and losses of 3,789.79 million yuan [2] Group 3: Reasons for Performance Changes - The company's main business remains stable, but increased strategic investments in new technology platforms and expansion in domestic and international markets have led to higher costs. Additionally, U.S. tariffs have reduced orders in certain regions, contributing to increased operating costs and a decline in profits due to exchange rate fluctuations, reduced interest income, and asset depreciation [4] Group 4: Fundraising Project Delay - The company has decided to postpone the completion date of the "in vitro diagnostic reagents and diagnostic instruments R&D and production project" from January 2026 to January 2027, without changing the investment content or total amount [9][10] - The delay is due to construction progress being slowed by global respiratory infectious diseases, affecting internal and external renovations, and the need for further payments related to the project [11][12] - The postponement is a prudent decision based on the actual situation of the project and will not adversely affect the company's normal operations or long-term development plans [12]

Group 1: Shareholder and Management Reduction of Holdings - Shareholders Zhu Wenyi and Liu Hui held 31,518,408 shares and 31,528,771 shares respectively, each accounting for 5.22% of the total share capital before the reduction plan [2][3] - Zhu Wenyi planned to reduce holdings by up to 10,540,000 shares (1.75% of total shares), while Liu Hui planned to reduce by up to 7,460,000 shares (1.24% of total shares) [3] - As of January 29, 2026, Zhu Wenyi reduced holdings by 2,678,999 shares (0.44% of total shares), while Liu Hui did not reduce any shares [3][4] Group 2: 2025 Annual Performance Forecast - The company expects a net profit attributable to shareholders of the parent company to be between -565 million and -471 million yuan for the year 2025, indicating a loss compared to the previous year [6][7] - The expected net profit after deducting non-recurring gains and losses is projected to be between -588 million and -490 million yuan [8] - The decline in revenue is attributed to changes in the macroeconomic environment and the implementation of centralized procurement policies in the in vitro diagnostics industry, leading to a revenue decrease of approximately 15% compared to the previous year [9] Group 3: Reasons for Performance Decline - The main reasons for the expected loss include a decrease in product prices due to industry policies, fixed costs not decreasing in line with revenue, and anticipated goodwill impairment provisions of 180 million to 220 million yuan for underperforming subsidiaries [9]

Core Viewpoint - Mingde Biological is planning two acquisitions within a month, including a 51% stake in Hunan Lanyi Medical Equipment Co., Ltd. for 35.7 million yuan, despite Hunan Lanyi's negative net assets and consecutive losses [1][2]. Group 1: Acquisition Details - The acquisition of Hunan Lanyi aims to enhance synergy and core competitiveness, focusing on complementary industry chains to improve comprehensive service capabilities [1][2]. - Hunan Lanyi, established in September 2020, specializes in IVD instruments and reagents, recognized as a national high-tech enterprise and a "little giant" in specialized fields [2]. - The acquisition structure includes Mingde acquiring 51% of Hunan Lanyi, while related parties will hold an additional 20%, with plans for full control if performance targets are met [2][3]. Group 2: Financial Performance and Projections - Hunan Lanyi reported a net asset of -62.42 million yuan and consecutive losses of 20.68 million yuan in 2024 and 23.98 million yuan in the first three quarters of 2025 [1]. - Mingde Biological's projected net profit for 2025 is expected to decline by 75.85% to 83.9%, ranging from 12 million to 18 million yuan, primarily due to decreased investment income and increased credit impairment losses [5]. - The financial performance of Wuhan Bikaier, another target for acquisition, shows stable revenue and profit, with 2023 revenues of 168 million yuan and net profit of 12.64 million yuan [4].

Core Viewpoint - RunDa Medical (603108.SH) is expected to report a net loss attributable to shareholders of the parent company ranging from -565 million to -471 million yuan for the fiscal year 2025, indicating a decline compared to the previous year [1] Group 1: Financial Performance - The projected net profit attributable to shareholders, excluding non-recurring gains and losses, is expected to be between -588 million and -490 million yuan for 2025 [1] - The company's revenue is anticipated to decrease by approximately 15% compared to the same period last year due to changes in the domestic macro environment and the implementation of centralized procurement policies in the in-vitro diagnostics industry [1] Group 2: Operational Challenges - The decline in revenue and gross margin is attributed to the impact of external environmental changes and pricing pressures on products [1] - Despite efforts to enhance management efficiency and implement cost control measures, fixed costs such as depreciation and financing expenses have not decreased in proportion to the revenue decline [1] Group 3: Impairment and Credit Risks - The company expects to recognize goodwill impairment provisions ranging from 180 million to 220 million yuan for certain subsidiaries due to their underperformance [1] - There has been an extension in the collection period for accounts receivable, leading the company to make credit impairment provisions for related accounts [1]